SynthesisBMC pulmonary medicine2025
Causal association between plasma proteins and lung adenocarcinoma: a two-sample mendelian randomization study.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preliminary Exploration of Fluvastatin Inhibiting Proliferation, Migration and Invasion of Lung Cancer Cells and Reversing Paclitaxel Resistance: Mechanism Exploration Based on Multi-Omics Analysis.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study utilized Mendelian randomization (MR) to investigate the causal relationship between circulating plasma proteins and lung adenocarcinoma.
methodsWe obtained 734 circulating plasma protein data from genome-wide association studies (GWAS) as exposure factors and extracted single nucleotide polymorphisms (SNPs) as instrumental variables. And we obtained lung adenocarcinoma data (including 11,245 cases and 54,619 controls) from the IEU Open GWAS database as the outcome factor. The main analytical methods used are inverse-variance weighted (IVW) or Wald ratio to assess the causal relationship between circulating plasma protein levels and lung adenocarcinoma. Sensitivity analysis (leave one out method, heterogeneity and pleiotropy tests), external validation analysis, and meta-analysis after MR were used to evaluate the reliability of MR results. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the final screened plasma proteins.
resultsThrough the preliminary and external validation stages, ICAM5 (OR = 0.92, 95%CI: 0.89-0.95, P = 2.31 × 10
conclusionsICAM5, PCYOX1 and TYMP are associated with a decreased risk of lung adenocarcinoma. Plasma proteins may become new biological markers for lung adenocarcinoma, providing new insights into the prevention and treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.